You are here

  • Home
  • Archive
  • Volume 79, Issue 3
  • Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study

Article metrics

Article menu
Download PDFPDF
Rheumatoid arthritis
Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2024

AbstractFullPdf
Dec 201911352
Jan 20202041222125
Feb 2020120315671
Mar 202072813983
Apr 20205224831
May 20202993223
Jun 20202511713
Jul 20201161517
Aug 20201111210
Sep 20201452015
Oct 20201842813
Nov 2020138184
Dec 20201361611
Jan 2021178125
Feb 20211351210
Mar 20212171814
Apr 2021209124
May 202175108
Jun 2021963
Jul 202110106
Aug 2021431
Sep 20211295
Oct 2021173227
Nov 2021195165
Dec 202111843
Jan 202212796
Feb 202213252
Mar 2022125166
Apr 202211344
May 20222711923
Jun 2022166167
Jul 20221031110
Aug 2022129126
Sep 2022163112
Oct 20221402013
Nov 2022155113
Dec 202213422
Jan 202310094
Feb 2023137113
Mar 2023142146
Apr 20239373
May 202394148
Jun 202311543
Jul 20237573
Aug 20235185
Sep 2023911411
Oct 20234662
Nov 202313974
Dec 20238742
Jan 20248460
Feb 202411286
Mar 202411843
Total105641121636